Tag: Innate Immunity

Author Correction: β-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus

Correction to: Nature Immunology https://doi.org/10.1038/s41590-024-02041-2, published online 8 January 2025. In the version of the article initially published, there were duplicate graphs in Fig. 5a, where the bottom-right Ifnar1–/– panel was a duplicate of the top-left control. The corrected Fig. 5 is now available in the HTML and PDF versions of the article. Author informationAuthor… Continue reading Author Correction: β-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus

Cystic fibrosis damages the immune system early on

Despite new medication, cystic fibrosis often leads to permanent lung damage. Researchers have discovered that the disease causes changes in the immune system early in life, presumably even in newborns. These changes lead to frequent inflammation and are not affected by drugs targeting the altered mucus production.

A new way to detect inflammation

Nearly every disease has an inflammatory component, but blood tests can’t pinpoint inflammation in specific organs or tissues in the human body. Now researchers have developed a method to detect inflammation using antibodies, potentially leading to blood tests for disease-specific biomarkers such as for heart disease, Alzheimer’s disease and various cancers. Their breakthrough also holds… Continue reading A new way to detect inflammation

Granzyme K identified as key trigger of complement system in autoimmune diseases

Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system-a group of proteins that patrols our body, ever vigilant for signs of infection or injury. Now, over 100 years after the complement system was first described, researchers… Continue reading Granzyme K identified as key trigger of complement system in autoimmune diseases

Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens

Background Enhancing antigen cross-presentation is essential for the development of a tumor neoantigen vaccine. One approach is to stimulate antigen-presenting cells (APCs) to uptake neoantigens. Mycobacterium tuberculosis (MTb) contains pathogen-associated molecular patterns (PAMPs) recognized by APCs and adhesion molecules that facilitate MTb invasion of APCs. Therefore, we suggest using MTb as a carrier to enhance… Continue reading Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens

Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality

Background Natural Killer (NK) cells have intrinsic anticancer activity that can be redirected toward acute myeloid leukemia (AML) with chimeric antigen receptor (CAR) engineering. Here, we study the functional consequences of CAR binding affinity and targeted epitope on CAR-NK cell activation, cytolytic synapse formation, and antitumor activity. Methods We characterized NK-92 and primary NK cell… Continue reading Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights

Background OH2 is an oncolytic virus derived from herpes simplex virus type 2. A phase Ia/Ib clinical trial in China was conducted in patients with unresected stage III–IV melanoma, the majority of whom had the acral type, to assess the safety and preliminary efficacy of OH2. Methods The trial enrolled patients with histologically confirmed unresectable… Continue reading Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights

Clofarabine induces tumor cell apoptosis, GSDME-related pyroptosis, and CD8+ T-cell antitumor activity via the non-canonical P53/STING pathway

Background Clofarabine (Clo) is a Food and Drug Administration (FDA)-approved drug for the treatment of acute lymphoblastic leukemia; however, its effects on solid tumors remain largely unknown. Methods In vitro and in vivo experiments have demonstrated the cytotoxic effects of Clo on melanoma and lung cancer. The molecular mechanisms of Clo-induced tumor cell death were… Continue reading Clofarabine induces tumor cell apoptosis, GSDME-related pyroptosis, and CD8+ T-cell antitumor activity via the non-canonical P53/STING pathway